Skip to content
Screener

Reported November 12, 2026 · Before market open

EPS-$0.11Beat by $0.04
Revenue estimate$1.0M
EPS estimate-$0.15
“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104. Our dual-source manufacturing strategy to address potential remediation issues at our current contract manufacturer is progressing, and the timing of our NDA resubmission will reflect whichever manufacturing site reaches readiness first. The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission. We look forward to reporting our progress as we work toward achieving these important milestones.”
Prashant Kohli

Next report

Feb 15, 2027 (in 3 months)
Revenue estimate$2.3M
EPS estimate-$0.15

FAQ

When did Grace Therapeutics, Inc. report Q2 2027 earnings?
Grace Therapeutics, Inc. (GRCE) reported Q2 2027 earnings on November 12, 2026 before market open.
What were Grace Therapeutics, Inc.'s Q2 2027 revenue and EPS?
Grace Therapeutics, Inc. reported eps of $-0.11 for Q2 2027.
Did Grace Therapeutics, Inc. beat estimates in Q2 2027?
EPS beat the consensus estimate of $-0.15 by $0.04.
How did Grace Therapeutics, Inc.'s Q2 2027 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 26.7% from $-0.15.
Where can I find Grace Therapeutics, Inc.'s Q2 2027 SEC filings?
You can read the 8-K earnings release (0001140361-26-043308) and the 10-Q periodic report (0001140361-26-043299) directly on SEC EDGAR. The filing index links above go to sec.gov.